BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Business

  Dr. David A. Evans, Chief Executive Of WellGen, Inc., Passes Away After Sudden Illness

  June 5, 2006

   · 

  2 min read
• Drug Development

  Exelixis, Inc.’ XL880, The First Orally-Available MET Inhibitor In Clinical Development, Continues To Show Promise In A Phase I Trial In Patients With Advanced Solid Tumors

  June 5, 2006

   · 

  7 min read
• Drug Development

  Sanofi-Aventis (France) Release: Results Of A Meta-Analysis Show Benefits Of Taxotere(R) (Docetaxel) Regimens In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

  June 5, 2006

   · 

  6 min read
• Drug Development

  Wyeth Announces Preliminary Results Of An Ongoing Study Of Temsirolimus For The Treatment Of Advanced Renal Cell Carcinoma As Presented At American Society of Clinical Oncology

  June 5, 2006

   · 

  5 min read
• Drug Development

  Cell Therapeutics, Inc. Data From XYOTAX(TM) STELLAR Trials Presented At 2006 Meeting Of American Society of Clinical Oncology

  June 5, 2006

   · 

  7 min read
• Drug Development

  AstraZeneca PLC Release: Results Of Phase II Studies Measure Progression Free Survival For ZACTIMA(TM) (ZD6474) In Lung Cancer

  June 5, 2006

   · 

  5 min read
• Drug Development

  Cell Genesys, Inc. Recaps Two Weekend Data Presentations From 2006 Medarex, Inc. Annual Meeting

  June 5, 2006

   · 

  5 min read
• Drug Development

  Oncolytics Biotech Inc.'s Research Collaborators Present Positive REOLYSIN(R) Clinical Trial Data At American Society of Clinical Oncology Conference

  June 5, 2006

   · 

  6 min read
• Drug Development

  Medarex, Inc. Release: Interim Ipilimumab (MDX-010) Phase II Trial Results Indicate Well-Tolerated, Extended Dosing With Preliminary Evidence That Immune Activation May Reduce Relapse In The Adjuvant Setting In Melanoma

  June 5, 2006

   · 

  5 min read
• Drug Development

  Vion Pharmaceuticals Presents Data On Cloretazine(R) In Elderly De Novo Acute Myelogenous Leukemia At American Society of Clinical Oncology Meeting

  June 5, 2006

   · 

  5 min read